World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
70
Citations
23167
World Ranking
6890
National Ranking
3177

Wells A. Messersmith publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Wells A. Messersmith sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 629 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Wells A. Messersmith D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Wells A. Messersmith sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 70 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Wells A. Messersmith is affiliated with the University of Colorado Boulder in the United States. Their primary research area lies within Medicine, with a strong focus on Oncology, encompassing 145 publications in this subfield. Additional subfields include Pulmonary and Respiratory Medicine, Cancer Research, Immunology, and Surgery. Their work spans various cancer-related topics and clinical research.

The scientist's research concentrates on several key topics, including:

  • Pancreatic and Hepatic Oncology Research
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Genetic factors in colorectal cancer
  • Neuroendocrine Tumor Research Advances
  • Gastric Cancer Management and Outcomes

Messersmith has contributed to multiple publications in prestigious journals. Frequent publication venues for their research include:

  • Journal of Clinical Oncology
  • Journal of the National Comprehensive Cancer Network
  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Clinical Cancer Research

Several recent papers authored or co-authored by Messersmith illustrate a focus on gastrointestinal cancers and emerging cancer therapies. These include:

  • "Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology," 2021, Journal of the National Comprehensive Cancer Network
  • "Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology," 2022, Journal of the National Comprehensive Cancer Network
  • "NCCN Guidelines Insights: Rectal Cancer, Version 6.2020," 2020, Journal of the National Comprehensive Cancer Network
  • "Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial," 2021, Annals of Oncology
  • "Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas," 2021, Clinical Cancer Research

Frequent collaborators in their research include Christopher H. Lieu, Alexis D. Leal, Todd M. Pitts, Robert W. Lentz, and S. Lindsey Davis. These co-authors have contributed significantly to multi-author publications alongside Messersmith, reflecting collaborations in clinical oncology and cancer research.

Best Publications

  • Patient-derived tumour xenografts as models for oncology drug development

    John J. Tentler;Aik Choon Tan;Colin D. Weekes;Antonio Jimeno

  • Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    Al B. Benson;Alan P. Venook;Mahmoud M. Al-Hawary;Mustafa A. Arain

  • Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

    Al B. Benson;Alan P. Venook;Lynette Cederquist;Emily Chan

  • NCCN Guidelines® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines

    Al B Benson;Alan P. Venook;Mahmoud M. Al-Hawary;Lynette Cederquist

  • Rectal cancer, version 2.2018 clinical practice guidelines in Oncology

    Al B Benson;Alan P. Venook;Mahmoud M. Al-Hawary;Lynette Cederquist

  • Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

    Gerald S Falchook;Karl D Lewis;Jeffrey R Infante;Michael S Gordon

  • Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

    Jeffrey R. Infante;Leslie A. Fecher;Gerald S. Falchook;Sujatha Nallapareddy

  • Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-Mutant colorectal cancer

    Ryan B. Corcoran;Chloe E. Atreya;Gerald S. Falchook;Eunice L. Kwak

  • An In vivo Platform for Translational Drug Development in Pancreatic Cancer

    Belen Rubio-Viqueira;Antonio Jimeno;George Cusatis;Xianfeng Zhang

  • Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A. Mayer;Jennifer R. Diamond;Rebecca L. Moroose

  • Rectal cancer, version 6.2020: Featured updates to the NCCN guidelines

    Al B. Benson;Al B. Benson;Alan P. Venook;Alan P. Venook;Mahmoud M. Al-Hawary;Mahmoud M. Al-Hawary;Mustafa A. Arain;Mustafa A. Arain

  • Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

    Anthony W. Tolcher;Wells A. Messersmith;Stanislaw M. Mikulski;Kyriakos P. Papadopoulos

  • KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection

    Antonio Jimeno;Wells A. Messersmith;Fred R. Hirsch;Wilbur A. Franklin

  • Rectal cancer, version 2.2015: Featured updates to the NCCN guidelines

    Al B. Benson;Alan P. Venook;Tanios Bekaii-Saab;Emily Chan

  • The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.

    Ihab R. Kamel;David A. Bluemke;John Eng;Eleni Liapi

  • Colon Cancer, Version 3.2014

    Al B. Benson;Alan P. Venook;Tanios Bekaii-Saab;Emily Chan

  • A phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014

    Wells A. Messersmith;Geoffrey I. Shapiro;James M. Cleary;Antonio Jimeno

  • A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

    David S. Hong;Daniel W. Bowles;Gerald S. Falchook;Wells A. Messersmith

  • Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.

    A. Bardia;W.A. Messersmith;E.A. Kio;J.D. Berlin

  • Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

    Allyson J. Ocean;Alexander N. Starodub;Aditya Bardia;Linda T. Vahdat

Frequent Co-Authors

Antonio Jimeno
Antonio Jimeno University of Colorado Boulder
Manuel Hidalgo
Manuel Hidalgo Cornell University
Aik Choon Tan
Aik Choon Tan University of Utah
Jordan Berlin
Jordan Berlin Vanderbilt University Medical Center
David M. Goldenberg
David M. Goldenberg Immunomedics (United States)
Robert M. Sharkey
Robert M. Sharkey University of Fukui
Sharyn D. Baker
Sharyn D. Baker The Ohio State University
Ross C. Donehower
Ross C. Donehower Johns Hopkins University
Martin D. McCarter
Martin D. McCarter University of Colorado Anschutz Medical Campus
Aditya Bardia
Aditya Bardia Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees and career pathways is a great way to shape your future in Biology and Biochemistry. Many students consider top dietetics programs in the us as a next step, blending biology knowledge with nutrition science to pursue licensure as a registered dietitian.

If you’re interested in hands-on healthcare positions, look into online medical assistant programs with financial aid. These programs offer flexible pathways into medical support roles and often include financial support options to help make your education affordable.

For those already working as medical assistants and seeking career growth, an ma to lpn bridge program can help you transition into a Licensed Practical Nurse role, expanding your scope of practice and earning potential.

Finally, students looking for a fast-track bachelor's degree in biology should consider online biology programs with accelerated options, which are ideal for motivated learners eager to advance quickly.

Best Scientists Citing Wells A. Messersmith

Trending Scientists

Recently Published Articles